Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
Showing 1862 results
October 2017
-
Story Access to Healthcare
Talking to: Patrice Matchaba, Global Head of Corporate Responsibility for Novartis
Dr. Matchaba describes how his unique background can help guide the company’s access-to-medicine efforts.
-
Press Release
Alcon introduces new innovations in cataract surgery at European Society of Cataract & Refractive Surgeons 2017 annual congress
Clareon® intraocular lens (IOL) implanted with a unique single-use automated pre-loaded delivery system debuts with new data presentations Congress program highlights Alcon's 70-year legacy…
September 2017
-
Story Access to Healthcare
Living with hypertension in Cameroon on a few dollars per day
In Cameroon, seeking treatment for chronic diseases can be a long journey.
-
Story Discovery
Novartis and UC Berkeley take on “undruggable” proteins in new collaboration
Researchers from industry and academia will leverage new chemistry to hit difficult drug targets.
-
In The News
Novartis Access and government of Cameroon sign agreement to fight chronic diseases
Cameroon faces a serious increase in chronic diseases like heart disease, asthma, cancer and diabetes. This agreement complements the government’s ongoing efforts by improving access to affordable… -
Press Release
Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets
Collaboration aims to unlock difficult drug targets and accelerate the discovery of new medicines in areas such as infectious diseases and cancer New Novartis-Berkeley Center for Proteomics and… -
Press Release
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
CMLPath to Care(TM) collaboration replaces Glivec International Patient Access Program (GIPAP) with a new, independent, patient-centered access model GIPAP was introduced 15 years ago and has… -
Press Release
Novartis drug Rydapt® (midostaurin) receives EU approval for newly diagnosed FLT3-mutated acute myeloid leukemia (AML) and three types of advanced systemic mastocytosis (SM)
Significant overall survival benefit seen with Rydapt, the first targeted treatment for newly diagnosed FLT3-mutated AML approved in the EU[1] As the first and only therapy for advanced SM… -
Story Patient Perspectives
Led by Steven Taylor, the Sjögren’s Syndrome Foundation is raising awareness of a little-known autoimmune disease
-
Press Release
Novartis' Xolair® confirms re-treatment efficacy in chronic spontaneous urticaria patients after treatment interruption
OPTIMA Phase IIIb data re-confirm that almost two thirds of patients treated with Xolair 300 mg for 6 months are well-controlled[1] Should a treatment pause be necessary, data showed almost… -
Press Release
Sandoz proposed biosimilar adalimumab matches reference biologic in terms of efficacy and safety in long-term study
51-week clinical study confirms that Sandoz proposed biosimilar adalimumab matches reference medicine Humira®* safety and efficacy profile[1]Sandoz proposed biosimilar adalimumab is currently under… -
Press Release
Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data
Cosentyx® (secukinumab) is the first and only fully human IL-17A inhibitor to show sustained skin clearance rates at 5 years in phase III in psoriasis[1] Landmark data show that PASI…